SCHEMBL578148

SCHEMBL578148

COC(=O)C1CCc2ccccc2C1=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 3/20 0.50
SMN1; SMN2 Q16637 2/20 0.49
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
PTGS2 P35354 3/20 0.47
ALDH1A1 P00352 4/20 0.47
KDM4E B2RXH2 3/20 0.47
MAPT P10636 2/20 0.47
TSHR P16473 1/20 0.47
HSD17B10 Q99714 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
CYP19A1 P11511 2/20 0.47
PIN1 Q13526 1/20 0.43
IDH1 O75874 1/20 0.42
HPGD P15428 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
TP53 P04637 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30023013 1.00 ACHE (0.50) ACHESMN1; SMN2NPC1RAB9APTGS2
SCHEMBL2166539 0.91 NPC1 (0.44) ACHESMN1; SMN2NPC1RAB9APTGS2
SCHEMBL4875547 0.90 SMN1; SMN2 (0.43) ACHESMN1; SMN2NPC1RAB9APTGS2
SCHEMBL1000380 0.84 ACHE (0.51) ACHESMN1; SMN2RAB9AALDH1A1KDM4E
SCHEMBL29476747 0.84 ACHE (0.51) ACHESMN1; SMN2RAB9AALDH1A1KDM4E
SCHEMBL947365 0.84 ALDH1A1 (0.55) ACHESMN1; SMN2NPC1RAB9APTGS2
SCHEMBL31522711 0.84 ACHE (0.47) ACHESMN1; SMN2NPC1RAB9APTGS2
SCHEMBL29683518 0.84 ALDH1A1 (0.55) ACHESMN1; SMN2NPC1RAB9APTGS2
SCHEMBL7755671 0.82 FAAH (0.43)
SCHEMBL29458360 0.82 ACHE (0.53) ACHESMN1; SMN2NPC1RAB9APTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008100618-A2 CARBON-LINKED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S SUNESIS PHARMACEUTICALS, INC. (US) 2008-08-21 WO claimed
US-20240018145-A1 POLYCYCLIC CAP-DEPENDENT ENDONUCLEASE INHIBITORS FOR TREATING OR PREVENTING INFLUENZA MERCK SHARP & DOHME LLC (US) 2024-01-18 US disclosed
US-20240018145-A1 POLYCYCLIC CAP-DEPENDENT ENDONUCLEASE INHIBITORS FOR TREATING OR PREVENTING INFLUENZA MERCK SHARP & DOHME LLC (US) 2024-01-18 US disclosed
CN-113563167-B Preparation method of 2-methyl-1-tetralone 南通华祥医药科技有限公司 2023-09-08 CN disclosed
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 US disclosed
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 US disclosed
US-20230159439-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 US disclosed
US-20230159439-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 US disclosed
CN-113121338-B Synthetic method of alpha-hydroxy-beta-keto acid ester compound 浙江工业大学 2022-10-28 CN disclosed
CN-114539055-A Method for realizing phase transfer catalysis beta-dicarbonyl compound alkylation reaction by using microchannel reactor 西安近代化学研究所 2022-05-27 CN disclosed
US-20070197581-A1 Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors MERCK SHARP & DOHME LLC 2007-08-23 US disclosed
US-20070197581-A1 Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors MERCK SHARP & DOHME LLC 2007-08-23 US disclosed
WO-2007084595-A2 CARBOCYCLIC AND HETEROCYCLIC ARYLSULFONES AS GAMMA SECRETASE INHIBITORS SCHERING CORPORATION (US) 2007-07-26 WO disclosed
CN-1839116-A Asymmetric urea compound and process for producing asymmetric compound by asymmetric conjugate addition reaction with the same as catalyst SUMITOMO CHEMICAL CO (JP) 2006-09-27 CN disclosed
US-20060194986-A1 Production methods of optically active hydrazine compound and optically active amine compound KYOTO UNIVERSITY SUMITOMO CHEMICAL COMPANY, LIMITED 2006-08-31 US disclosed
US-20060161006-A1 Asymmetric urea compound and process for producing asymmetric compound by asymmetric conjugate addition reaction with the same as catalyst SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-07-20 US disclosed
EP-1640361-A2 ASYMMETRIC UREA COMPOUND AND PROCESS FOR PRODUCING ASYMMETRIC COMPOUND BY ASYMMETRIC CONJUGATE ADDITION REACTION WITH THE SAME AS CATALYST SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-03-29 EP disclosed
US-6211212-B1 DRUGS WITH AMIDE AND ESTER GROUPS AS ENZYME INHIBITORS SMITHKLINE BEECHAM P.L.C. (GB) 2001-04-03 US disclosed
EP-0888347-A1 PHARMACEUTICALLY USEFUL COMPOUNDS Astra Pharmaceuticals Limited (GB) 1999-01-07 EP disclosed
WO-1997034893-A1 PHARMACEUTICALLY USEFUL COMPOUNDS ASTRA PHARMACEUTICALS LTD. (GB) 1997-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159439-A1 ARYLAMIDES AND METHODS OF USE THEREOF CFTR, AADAC, ARSA ACHE 3394/4885SMN1; SMN2 2207/4885NPC1 106/4885
US-20240018145-A1 POLYCYCLIC CAP-DEPENDENT ENDONUCLEASE INHIBITORS FOR TREATING OR PREVENTING INFLUENZA DNASE1, RNASEH1, RNASE1 ACHE 2577/4885SMN1; SMN2 4318/4885NPC1 902/4885
US-20070197581-A1 Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors BACE1, BACE2, PSEN1 ACHE 37/4885SMN1; SMN2 2264/4885NPC1 1820/4885
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF CFTR, AADAC, ARSA ACHE 3394/4885SMN1; SMN2 2207/4885NPC1 106/4885
US-20060161006-A1 Asymmetric urea compound and process for producing asymmetric compound by asymmetric conjugate addition reaction with the same as catalyst RAD18, UTP18, UBE2G2 ACHE 395/4885SMN1; SMN2 3578/4885NPC1 3149/4885
US-20060194986-A1 Production methods of optically active hydrazine compound and optically active amine compound H1-0, H1-5, H1-10 ACHE 166/4885SMN1; SMN2 4454/4885NPC1 2604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.